Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Nyxoah reported preliminary Q2 revenue of €7.7 million, representing 21% sequential growth, driven by a 22% increase in U.S. sales to €5.2 million. Operational momentum remained strong with 89 new accounts activated and 180 active high-volume HGNS accounts, alongside proposed CMS reimbursement increases of 12% for hospitals and 15% for ASCs.
Key figures
- Revenue
- €7.7 million
- Guidance
- €36 million to €40 million
- Us revenue
- €5.2 million
- Cash position
- €97.8 million
- Active accounts
- 180
- Surgeons trained
- 262
- Financing secured
- $110 million
- Us revenue seq growth
- 22%
- Global revenue seq growth
- 21%
- Cms asc reimbursement increase
- 15%
- Cms hospital reimbursement increase
- 12%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.